Try our Advanced Search for more refined results
Contract Research Solutions, Inc.
Case Number:
1:12-bk-11004
Court:
Nature of Suit:
Firms
- Blank Rome
- Bryan Cave
- Carlton Fields
- Ciardi Ciardi
- Eckert Seamans
- Elliott Greenleaf
- Ferry Joseph
- Foley & Lardner
- Giordano Halleran
- Hiller & Arban
- Latham & Watkins
- Lathrop GPM
- Linebarger Goggan
- Lowenstein Sandler
- Magnozzi & Kye
- Margolis Edelstein
- McCarter & English
- Morris James
- Pachulski Stang
- Paul Hastings
- Reed Smith
- Rosner Law Group LLC
- Sullivan Hazeltine
- Warner Norcross
- White and Williams
- Willkie Farr
- Wilson Elser
- Womble Bond
- Young Conaway
Companies
- Allergan PLC
- Anchen Pharmaceuticals Inc.
- Apotex Inc.
- Beckman Coulter Inc.
- Bristol-Myers Squibb Co.
- Cardinal Health Inc.
- Cetero Research
- Covidien PLC
- Galderma SA
- GreatAmerica Financial Services
- Iron Mountain Inc.
- Kythera Biopharmaceuticals Inc.
- LEO Pharma AS
- Novum Pharmaceutical Research Services of Pennsylvania Inc.
- Oracle Corp.
- Osmotica Pharmaceutical Corp.
- Par Pharmaceutical Cos. Inc.
- Perrigo Co. PLC
- Phadia
- Quest Diagnostics Inc.
- Teva Pharmaceutical Industries Ltd.
- tw telecom inc.
Government Agencies
- Colorado Department of Labor and Employment
- Missouri Department of Revenue
- Texas Comptroller of Public Accounts
Sectors & Industries:
-
May 17, 2012
Cetero Purchased By Creditors In $80M Stalking Horse Deal
A Delaware bankruptcy judge on Thursday approved the sale of pharmaceutical testing company Cetero Research to its secured creditors in a stalking horse deal worth approximately $80 million.
-
April 24, 2012
Research Co. Makes Peace With FDA Over Suspect Drug Tests
Bankrupt Cetero Research has reached a final resolution with the U.S. Food and Drug Administration over data irregularities at one of the pharmaceutical testing provider's labs, the company said Tuesday.
-
April 13, 2012
Cetero Gets Nod To Auction Assets In Ch. 11
Bankrupt Cetero Research won court approval Friday in Delaware to auction off its assets, with secured lenders poised to take control of the beleaguered pharmaceutical testing company through an $80.3 million stalking horse bid.